Guillermo López-Vivanco

13.4k total citations
116 papers, 2.1k citations indexed

About

Guillermo López-Vivanco is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Guillermo López-Vivanco has authored 116 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 29 papers in Cancer Research. Recurrent topics in Guillermo López-Vivanco's work include Lung Cancer Treatments and Mutations (40 papers), Cancer Treatment and Pharmacology (25 papers) and Colorectal Cancer Treatments and Studies (22 papers). Guillermo López-Vivanco is often cited by papers focused on Lung Cancer Treatments and Mutations (40 papers), Cancer Treatment and Pharmacology (25 papers) and Colorectal Cancer Treatments and Studies (22 papers). Guillermo López-Vivanco collaborates with scholars based in Spain, France and United Kingdom. Guillermo López-Vivanco's co-authors include Rafael Rosell, Carlos Camps, Dolores Isla, Mariano Provencio, Manuel Dómine, Miquel Tarón, Bartomeu Massutí, José Javier Sánchez, Ana Fernández Montés and Luis Paz‐Ares and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Guillermo López-Vivanco

113 papers receiving 2.0k citations

Peers

Countries citing papers authored by Guillermo López-Vivanco

Since Specialization

Citations

This map shows the geographic impact of Guillermo López-Vivanco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guillermo López-Vivanco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guillermo López-Vivanco more than expected).

Fields of papers citing papers by Guillermo López-Vivanco

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guillermo López-Vivanco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guillermo López-Vivanco. The network helps show where Guillermo López-Vivanco may publish in the future.

Co-authorship network of co-authors of Guillermo López-Vivanco

This figure shows the co-authorship network connecting the top 25 collaborators of Guillermo López-Vivanco. A scholar is included among the top collaborators of Guillermo López-Vivanco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guillermo López-Vivanco. Guillermo López-Vivanco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Just an Acute Pulmonary Edema? Paraneoplastic Thyroid Storm Due to Invasive Mole 2022 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), Guillermo López-Vivanco	4
2	157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy 2022 ·Annals of Oncology ·Marta Casarrubios, Alberto Cruz‐Bermúdez, (unknown), Ernest Nadal, (unknown), (unknown), (unknown), M. Dómine Gómez, M. Majem Tarruella, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, (unknown), Manuel Cobo, Guillermo López-Vivanco, Núria Segarra, (unknown), Santiago Viteri, (unknown), Mariano Provencio	1
3	Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study 2021 ·Cancer Chemotherapy and Pharmacology ·Jaime Feliú, (unknown), Teresa Macarulla, Bartomeu Massutí, (unknown), (unknown), (unknown), (unknown), Ana Fernández Montés, (unknown), Manuel Valladares‐Ayerbes, (unknown), (unknown), Pilar Vicente, (unknown), (unknown), Guillermo López-Vivanco	12
4	First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met 2021 ·European Journal of Cancer ·Margarita Majem, (unknown), Santiago Viteri, Guillermo López-Vivanco, Manuel Cobo, José Miguel Sánchez, Jorge García, J. Garde, (unknown), (unknown), Andrea Malfettone, Niki Karachaliou, Miguel Ángel Molina‐Vila, Rafael Rosell	4
5	LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial 2020 ·Annals of Oncology ·Solange Peters, J.L. Pujol, Urania Dafni, Manuel Dómine, (unknown), J. Andrade, Alessandra Curioni‐Fontecedro, O. Molinier, Denis Moro‐Sibilot, Kristiaan Nackaerts, (unknown), Guillermo López-Vivanco, J. Madelaine, Sanjay Popat, Martin Reck, Heidi Roschitzki‐Voser, Paul Mitchell, Dirk De Ruysscher, C. Le Péchoux, Rolf A. Stahel	12
6	EP1.04-07 Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Guillermo López-Vivanco	1
7	Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study 2018 ·OncoTargets and Therapy ·Andrés Redondo, Manuel Ramos Vázquez, Luís Manso, Miguel Gil‐Gil, (unknown), Elisa García-Garré, César A. Rodríguez, José Ignacio Chacón, Guillermo López-Vivanco	5
8	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Niki Karachaliou, Jillian Wilhelmina Paulina Bracht, (unknown), Ana Drozdowskyj, Ana Giménez‐Capitán, Teresa Morán, Enric Carcereny, Manuel Cobo, Manuel Dómine, Imane Chaib, José Luis Ramírez, Carlos Camps, Mariano Provencio, A. Vergnenègre, Guillermo López-Vivanco, Margarita Majem, Bartomeu Massutí, Rafael Rosell	13
9	147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study 2016 ·Journal of Thoracic Oncology ·Edurne Arriola, Alfredo Paredes, Ramón García Gómez, Pilar Díz, Manuel Constenla, Carlos García Girón, (unknown), Martin Reck, Guillermo López-Vivanco	1
10	Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial 2015 ·BMC Cancer ·(unknown), (unknown), (unknown), Verónica Arce, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Guillermo López-Vivanco, Gonzalo Grandes	14
11	A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis 2014 ·Journal of Thoracic Oncology ·(unknown), Itsaso Hormaeche, Rafael Zalacaín, Guillermo López-Vivanco, Antonio Martı́nez, Daniel Nagore, M. Begoña Ruiz-Argüello	39
12	Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells 2012 ·Molecular Cancer ·Aitziber Buqué, (unknown), Alberto Múñoz, Begoña Calvo, (unknown), (unknown), (unknown), (unknown), Guillermo López-Vivanco	34
13	Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial 2011 ·Annals of Oncology ·Daniel Rayson, Thomas Suter, Christian Jackisch, S. van der Vegt, Begoña Bermejo, Jackie Bosch, Guillermo López-Vivanco, (unknown), Hans Wildiers, A. Antón Torres, Louise Provencher, (unknown), Jacquie Chirgwin, Jean Luc Canon, Gabriella Ferrandina, S. Srinivasan, (unknown), D. J. Richel	33
14	First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study 2011 ·Annals of Oncology ·Laura Biganzoli, (unknown), Zefei Jiang, Mikhail Lichinitser, (unknown), R. Delva, Natalia Bogdanova, Guillermo López-Vivanco, (unknown), Ying Cheng, Marianne Just, Marc Espié, J. Vinholes, Caroline Hamm, Diana Crivellari, Ewa Chmielowska, Semiglazov Vf, Florence Dalenc, Ian Smith	44
15	Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients 2009 ·Lung Cancer ·Enric Carcereny, José Luis Ramírez, María Sanchez-Ronco, Dolores Isla, Manuel Cobo, Teresa Morán, Itziar de Aguirre, Tatsuro Okamoto, Jia Wei, Mariano Provencio, Guillermo López-Vivanco, Carlos Camps, Manuel Dómine, Vicente Alberola, José Miguel Sánchez, Bartomeu Massutí, Pedro Méndez, Miquel Tarón, Rafael Rosell	9
16	Cisplatin-Based Three Drugs Combination (NIP) as Induction and Adjuvant Treatment in Locally Advanced Non-small Cell Lung Cancer: Final Results 2008 ·Journal of Thoracic Oncology ·Maya Gottfried, Rodryg Ramlau, Maciej Krzakowski, (unknown), (unknown), Leona Koubková, Jubrail Dahabreh, Aleksandra Szczęsna, Guillermo López-Vivanco, Reury-Perng Perng, Francesco Carpagnano, Swan-Swan Leong, A. Fittipaldo, (unknown), D. Aubert, Dominique Grunenwald	23
17	P2-087: Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (p) 2007 ·Journal of Thoracic Oncology ·Miguel Ángel Molina‐Vila, R. de las Peñas, Vicente Alberola, Ana Blasco, Guillermo López-Vivanco, Marta López Brea, J.L. González-Larriba, (unknown), José Luis Ramírez, Rafael Rosell	1
18	Factores pronósticos y predictivos en pacientes con cáncer de origen desconocido tratados con un esquema de quimioterapia con paclitaxel 2004 ·Medicina Clínica ·Alberto Múñoz, N. Fuente, Ramón Barceló, (unknown), (unknown), Guillermo López-Vivanco	0
19	Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer 2004 ·Annals of Oncology ·Dolores Isla, Carme Sarries, Rafael Rosell, G. Alonso, Manuel Dómine, Miquel Tarón, Guillermo López-Vivanco, Carlos Camps, Mónica Botia, L. Núñez, M. Sánchez-Ronco, José Javier Sánchez, M. López-Brea, I. Barneto, Alfredo Paredes, (unknown), Á. Artal, P. Lianes	255
20	Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: Description of four cases 2000 ·Annals of Oncology ·Ramón Barceló, Guillermo López-Vivanco, (unknown), (unknown), Alberto Múñoz, Ricardo Fernández	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact